Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07237308 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis

StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Yonsei University
239 trials monitored
See 2 trials at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Stroke
3,531 trials monitored
See 153 trials at risk
Atrial Fibrillation
1,182 trials monitored
See 50 trials at risk
This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic intracranial or extracranial atherosclerosis. Participants will be randomly assigned in a 1:1 ratio to receive apixaban monotherapy or dual therapy with clopidogrel for 30 days. The primary outcome is the incidence of symptomatic or asymptomatic recurrent ischemic lesions detected on brain MRI (DWI/FLAIR) at 30 ± 5 days after initiation of study medication.
Trial Details
NCT Number NCT07237308
Lead Sponsor Yonsei University
Conditions
(from sponsor)		 Stroke, Ischemic, Atrial Fibrillation, Intracrnaial Arterioscelrosis, Arteriosclerosis
Related terms Arteriosclerosis, Atrial Fibrillation, Ischemia, Stroke
Enrollment 586 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov